Biosimilars Immunology Roundup for July 2023—Podcast Edition
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
Show Notes
First Round of Adalimumab Biosimilar Launches in July
Celltrion Launches Yuflyma on the US Market
US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market
Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches
Multiple Infliximab Biosimilar Switches Were Safe, Effective
Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis
Biosimilar, Innovator Romiplostim Comparably Safe and Effective
